... at NewYork-Presbyterian/Columbia, now focusing on determining how the drug works in T-cell lymphoma, and on how best to combine it with other drugs to improve the treatment of patient with ...
... works by mimicking folic acid, showed a complete or partial response in 27 percent of patients with recurrent or resistant peripheral T-cell lymphoma.
... are two types of lymphoma: B cell lymphomas and T cell lymphomas. Both B ... it right, but it only takes one mistake in one of a hundred million cells to cause a problem. "
The paper follows a similar ...
WASHINGTON, Sept. 28 (UPI) -- The U.S. Food and Drug Administration has approved Folotyn as the first treatment for a form of cancer known as peripheral T-cell lymphoma.
... approximately 66,000 new cases of lymphoma and nearly 20,000 deaths each ... patients with relapsed or refractory peripheral T-cell lymphoma, found that the investigational chemotherapy agent pralatrexate ...
... iron. However, high levels of iron in the cell lead to the production of extremely harmful free ... extremely aggressive type of cutaneous T cell lymphoma. The majority of currently available treatments ...
... Panobinostat is approved as therapy for cutaneous T cell lymphoma (CTCL), and rapamycin is best known ... studied the combination of agents in pancreatic cancer cells because her previous research at Mayo ...
Researchers have identified a key mechanism that causes chromosomes within blood cells to break -- an occurrence that marks the first step in the development of human lymphoma.
... a novel targeted agent that has recently been approved for the treatment of cutaneous T-cell lymphoma. They found that this combination leads to a dramatic induction of apoptosis, or programmed cell ...
... coast of Key Largo that inhibits cancer cell growth in laboratory tests, a finding they hope ... targeted by a drug approved for cutaneous T-cell lymphoma manufactured by the global pharmaceutical company ...
... . Another HDAC suppressor, marketed as Zolinza, has now been approved for the treatment of T-cell lymphoma, Hong said. Others, including FK228, are undergoing clinical trials as anti-cancer drugs.
...
... expressed in 30 percent of IBC cases; another examines the use of vorinostat, a drug commonly used to treat cutaneous T-cell lymphoma, to treat the aggressive cases of IBC that recur on ...
WASHINGTON, Nov. 9 (UPI) -- The U.S. Food and Drug Administration says it has approved a new treatment for patients with a rare form of cancer known as Cutaneous T-cell Lymphoma.
